Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers.

Pastorino F, Brignole C, Di Paolo D, Perri P, Curnis F, Corti A, Ponzoni M.

Small. 2019 Mar;15(10):e1804591. doi: 10.1002/smll.201804591. Epub 2019 Feb 1. Review.

PMID:
30706636
2.

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma.

Morandi F, Frassoni F, Ponzoni M, Brignole C.

J Immunol Res. 2018 Oct 30;2018:8097398. doi: 10.1155/2018/8097398. eCollection 2018. Review.

3.

Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles.

Ponzoni M, Curnis F, Brignole C, Bruno S, Guarnieri D, Sitia L, Marotta R, Sacchi A, Bauckneht M, Buschiazzo A, Rossi A, Di Paolo D, Perri P, Gori A, Sementa AR, Emionite L, Cilli M, Tamma R, Ribatti D, Pompa PP, Marini C, Sambuceti G, Corti A, Pastorino F.

Small. 2018 Nov;14(45):e1802886. doi: 10.1002/smll.201802886. Epub 2018 Oct 7.

PMID:
30294852
4.

Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer.

Ponzoni M, Pastorino F, Di Paolo D, Perri P, Brignole C.

Int J Mol Sci. 2018 Jul 4;19(7). pii: E1953. doi: 10.3390/ijms19071953. Review.

5.

A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo.

Luli S, Di Paolo D, Perri P, Brignole C, Hill SJ, Brown H, Leslie J, Marshall HL, Wright MC, Mann DA, Ponzoni M, Oakley F.

J Hepatol. 2016 Jul;65(1):75-83. doi: 10.1016/j.jhep.2016.03.021. Epub 2016 Apr 9.

6.

A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects.

Piaggio F, Kondylis V, Pastorino F, Di Paolo D, Perri P, Cossu I, Schorn F, Marinaccio C, Murgia D, Daga A, Raggi F, Loi M, Emionite L, Ognio E, Pasparakis M, Ribatti D, Ponzoni M, Brignole C.

J Control Release. 2016 Feb 10;223:165-177. doi: 10.1016/j.jconrel.2015.12.037. Epub 2015 Dec 29. No abstract available.

PMID:
26742942
7.

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destafanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P.

Oncotarget. 2015 Oct 6;6(30):28774-89. doi: 10.18632/oncotarget.4342.

8.

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

Cossu I, Bottoni G, Loi M, Emionite L, Bartolini A, Di Paolo D, Brignole C, Piaggio F, Perri P, Sacchi A, Curnis F, Gagliani MC, Bruno S, Marini C, Gori A, Longhi R, Murgia D, Sementa AR, Cilli M, Tacchetti C, Corti A, Sambuceti G, Marchiò S, Ponzoni M, Pastorino F.

Biomaterials. 2015 Nov;68:89-99. doi: 10.1016/j.biomaterials.2015.07.054. Epub 2015 Aug 1.

9.

Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.

Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, Marchetti C, Minarini A, Cilli M, Emionite L, Di Paolo D, Brignole C, Piaggio F, Perri P, Tumiatti V, Pistoia V, Pagnan G, Ponzoni M.

J Control Release. 2015 Aug 10;211:44-52. doi: 10.1016/j.jconrel.2015.05.286. Epub 2015 May 29.

PMID:
26031842
10.

sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.

Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, Brignole C, Di Paolo D, Piaggio F, Perri P, Cilli M, Pastorino F, Ponzoni M.

J Control Release. 2014 Oct 28;192:157-66. doi: 10.1016/j.jconrel.2014.07.009. Epub 2014 Jul 17.

PMID:
25041999
11.

Quiescent hepatic stellate cells functionally contribute to the hepatic innate immune response via TLR3.

Wilson CL, Mann J, Walsh M, Perrugoria MJ, Oakley F, Wright MC, Brignole C, Di Paolo D, Perri P, Ponzoni M, Karin M, Mann DA.

PLoS One. 2014 Jan 8;9(1):e83391. doi: 10.1371/journal.pone.0083391. eCollection 2014.

12.

Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma.

Pastorino F, Brignole C, Loi M, Di Paolo D, Di Fiore A, Perri P, Pagnan G, Ponzoni M.

Front Oncol. 2013 Aug 5;3:190. doi: 10.3389/fonc.2013.00190. eCollection 2013.

13.

Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.

Di Paolo D, Pastorino F, Zuccari G, Caffa I, Loi M, Marimpietri D, Brignole C, Perri P, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M, Pagnan G.

J Control Release. 2013 Sep 28;170(3):445-51. doi: 10.1016/j.jconrel.2013.06.015. Epub 2013 Jun 19.

PMID:
23792118
14.

Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.

Loi M, Di Paolo D, Soster M, Brignole C, Bartolini A, Emionite L, Sun J, Becherini P, Curnis F, Petretto A, Sani M, Gori A, Milanese M, Gambini C, Longhi R, Cilli M, Allen TM, Bussolino F, Arap W, Pasqualini R, Corti A, Ponzoni M, Marchiò S, Pastorino F.

J Control Release. 2013 Sep 10;170(2):233-41. doi: 10.1016/j.jconrel.2013.04.029. Epub 2013 May 25.

15.

The use of the orthotopic model to validate antivascular therapies for cancer.

Loi M, Di Paolo D, Becherini P, Zorzoli A, Perri P, Carosio R, Cilli M, Ribatti D, Brignole C, Pagnan G, Ponzoni M, Pastorino F.

Int J Dev Biol. 2011;55(4-5):547-55. doi: 10.1387/ijdb.103230ml. Review.

16.

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P.

Mol Ther. 2011 Dec;19(12):2201-12. doi: 10.1038/mt.2011.142. Epub 2011 Aug 9.

17.

Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.

Di Paolo D, Brignole C, Pastorino F, Carosio R, Zorzoli A, Rossi M, Loi M, Pagnan G, Emionite L, Cilli M, Bruno S, Chiarle R, Allen TM, Ponzoni M, Perri P.

Mol Ther. 2011 Jun;19(6):1131-40. doi: 10.1038/mt.2011.54. Epub 2011 Apr 12.

18.

PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.

Bachetti T, Di Paolo D, Di Lascio S, Mirisola V, Brignole C, Bellotti M, Caffa I, Ferraris C, Fiore M, Fornasari D, Chiarle R, Borghini S, Pfeffer U, Ponzoni M, Ceccherini I, Perri P.

PLoS One. 2010 Oct 1;5(10). pii: e13108. doi: 10.1371/journal.pone.0013108.

19.

Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M.

Cancer Res. 2010 Dec 1;70(23):9816-26. doi: 10.1158/0008-5472.CAN-10-1251. Epub 2010 Oct 8.

20.

Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.

Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.

J Control Release. 2010 Jul 1;145(1):66-73. doi: 10.1016/j.jconrel.2010.03.015. Epub 2010 Mar 24.

PMID:
20346382
21.

Liposome-mediated therapy of neuroblastoma.

Di Paolo D, Loi M, Pastorino F, Brignole C, Marimpietri D, Becherini P, Caffa I, Zorzoli A, Longhi R, Gagliani C, Tacchetti C, Corti A, Allen TM, Ponzoni M, Pagnan G.

Methods Enzymol. 2009;465:225-49. doi: 10.1016/S0076-6879(09)65012-6.

PMID:
19913170
22.

Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.

Pastorino F, Di Paolo D, Loi M, Becherini P, Caffa I, Zorzoli A, Marimpietri D, Carosio R, Perri P, Montaldo PG, Brignole C, Pagnan G, Ribatti D, Allen TM, Ponzoni M.

Curr Drug Targets. 2009 Oct;10(10):1021-7. Review.

PMID:
19663770
23.

Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease.

Bacci M, Capobianco A, Monno A, Cottone L, Di Puppo F, Camisa B, Mariani M, Brignole C, Ponzoni M, Ferrari S, Panina-Bordignon P, Manfredi AA, Rovere-Querini P.

Am J Pathol. 2009 Aug;175(2):547-56. doi: 10.2353/ajpath.2009.081011. Epub 2009 Jul 2.

24.

The adenovirus E4orf4 protein induces G2/M arrest and cell death by blocking protein phosphatase 2A activity regulated by the B55 subunit.

Li S, Brignole C, Marcellus R, Thirlwell S, Binda O, McQuoid MJ, Ashby D, Chan H, Zhang Z, Miron MJ, Pallas DC, Branton PE.

J Virol. 2009 Sep;83(17):8340-52. doi: 10.1128/JVI.00711-09. Epub 2009 Jun 17.

25.

Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.

Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, Piccardi F, Cilli M, Tradori-Cappai A, Arrigoni G, Pistoia V, Ponzoni M.

J Control Release. 2009 Sep 1;138(2):122-7. doi: 10.1016/j.jconrel.2009.05.006. Epub 2009 May 7.

PMID:
19427884
26.

The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.

Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M.

Clin Cancer Res. 2009 Feb 15;15(4):1199-209. doi: 10.1158/1078-0432.CCR-08-2477.

27.

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.

Clin Cancer Res. 2008 Nov 15;14(22):7320-9. doi: 10.1158/1078-0432.CCR-08-0804.

28.

Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment.

Di Paolo D, Pastorino F, Brignole C, Marimpietri D, Loi M, Ponzoni M, Pagnan G.

Tumori. 2008 Mar-Apr;94(2):246-53.

PMID:
18564613
29.

Ligand-targeted liposomal therapies of neuroblastoma.

Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M.

Curr Med Chem. 2007;14(29):3070-8. Review.

PMID:
18220743
30.

Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.

Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M.

Clin Cancer Res. 2007 Jul 1;13(13):3977-88.

31.

Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M.

Cancer Res. 2006 Oct 15;66(20):10073-82.

32.

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.

J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57.

PMID:
16912267
33.

Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

Brignole C, Marimpietri D, Pagnan G, Di Paolo D, Zancolli M, Pistoia V, Ponzoni M, Pastorino F.

Cancer Lett. 2005 Oct 18;228(1-2):181-6. Review.

PMID:
15936140
34.

Caspase-8 gene expression in neuroblastoma.

Casciano I, Banelli B, Croce M, De Ambrosis A, di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M, Romani M.

Ann N Y Acad Sci. 2004 Dec;1028:157-67.

PMID:
15650242
35.

Angiogenesis in neuroblastoma.

Ribatti D, Marimpietri D, Pastorino F, Brignole C, Nico B, Vacca A, Ponzoni M.

Ann N Y Acad Sci. 2004 Dec;1028:133-42. Review.

PMID:
15650239
36.

Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.

Pastorino F, Brignole C, Marimpietri D, Di Paolo D, Zancolli M, Pagnan G, Ponzoni M.

Ann N Y Acad Sci. 2004 Dec;1028:90-103.

PMID:
15650235
37.

Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis.

Simile MM, Pagnan G, Pastorino F, Brignole C, De Miglio MR, Muroni MR, Asara G, Frau M, Seddaiu MA, Calvisi DF, Feo F, Ponzoni M, Pascale RM.

Carcinogenesis. 2005 Feb;26(2):417-27. Epub 2004 Oct 21.

PMID:
15498786
38.

Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

Brignole C, Pastorino F, Marimpietri D, Pagnan G, Pistorio A, Allen TM, Pistoia V, Ponzoni M.

J Natl Cancer Inst. 2004 Aug 4;96(15):1171-80.

PMID:
15292389
39.

Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.

Cancer Res. 2003 Nov 1;63(21):7400-9.

40.

Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.

Clin Cancer Res. 2003 Oct 1;9(12):4595-605.

41.

Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.

Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F.

Cancer Lett. 2003 Jul 18;197(1-2):231-5. Review.

PMID:
12880987
42.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
43.

Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.

Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F.

Cancer Lett. 2003 Jul 18;197(1-2):199-204. Review.

PMID:
12880982
44.

Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.

Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Bogenmann E, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):151-5. Review.

PMID:
12880975
45.

In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.

Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Montaldo PG, Gambini C, Allen TM, Bogenmann E, Ponzoni M.

Int J Cancer. 2003 May 1;104(5):559-67.

46.

Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.

Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M.

Cancer Res. 2003 Jan 1;63(1):86-92.

47.

Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region.

Banelli B, Casciano I, Croce M, Di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M, Romani M.

Nat Med. 2002 Dec;8(12):1333-5; author reply 1335. No abstract available.

PMID:
12457155
48.

In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.

Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M.

Int J Cancer. 2002 Dec 1;102(4):351-4.

Supplemental Content

Loading ...
Support Center